Hybridization of the Pharmacophoric Features of Discoipyrrole C and Combretastatin A-4 toward New Anticancer Leads

IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2023-05-31 DOI:10.1002/cmdc.202300081
Dr. Jais Kurian, Anvesh Ashtam, Dr. Akila Kesavan, Dr. Saheer V. Chaluvalappil, Dr. Dulal Panda, Dr. Muraleedharan K. Manheri
{"title":"Hybridization of the Pharmacophoric Features of Discoipyrrole C and Combretastatin A-4 toward New Anticancer Leads","authors":"Dr. Jais Kurian,&nbsp;Anvesh Ashtam,&nbsp;Dr. Akila Kesavan,&nbsp;Dr. Saheer V. Chaluvalappil,&nbsp;Dr. Dulal Panda,&nbsp;Dr. Muraleedharan K. Manheri","doi":"10.1002/cmdc.202300081","DOIUrl":null,"url":null,"abstract":"<p>Pharmacophore hybridization is an attractive strategy to identify new leads against multifactorial diseases such as cancer. Based on literature analysis of compounds possessing ‘vicinal diaryl’ fragment in their structure, we considered Discoipyrroles A−D and Combretastatin A-4 (<b>CA</b>-<b>4</b>) as possible components in hybrid design. Discoipyrrole C (<b>Dis C</b>) and <b>CA</b>-<b>4</b> were used as reference compounds in these studies and their hybrids, in the form of 4,5-diaryl-1<i>H</i>-pyrrol-3(2<i>H</i>)-ones, were synthesized from suitable amino acid precursors though their ynone intermediates. Of these, the hybrid having exact substitution pattern as that of <b>CA</b>-<b>4</b> showed better potency and selectivity than <b>Dis C</b>, but its activity was less compared to <b>CA</b>-<b>4</b>. This new analog disrupted interphase microtubules by inhibiting tubulin assembly by binding to the colchicine site, induced multipolar spindles, caused cell cycle block and apoptosis in HeLa cells. It also inhibited colony formation and migration of breast cancer cell lines.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202300081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmacophore hybridization is an attractive strategy to identify new leads against multifactorial diseases such as cancer. Based on literature analysis of compounds possessing ‘vicinal diaryl’ fragment in their structure, we considered Discoipyrroles A−D and Combretastatin A-4 (CA-4) as possible components in hybrid design. Discoipyrrole C (Dis C) and CA-4 were used as reference compounds in these studies and their hybrids, in the form of 4,5-diaryl-1H-pyrrol-3(2H)-ones, were synthesized from suitable amino acid precursors though their ynone intermediates. Of these, the hybrid having exact substitution pattern as that of CA-4 showed better potency and selectivity than Dis C, but its activity was less compared to CA-4. This new analog disrupted interphase microtubules by inhibiting tubulin assembly by binding to the colchicine site, induced multipolar spindles, caused cell cycle block and apoptosis in HeLa cells. It also inhibited colony formation and migration of breast cancer cell lines.

双吡咯C和比他他汀A-4对新型抗癌先导物的药理特性杂交研究
药效团杂交是一种有吸引力的策略,可用于识别针对癌症等多因子疾病的新线索。基于对结构中含有“邻二芳基”片段的化合物的文献分析,我们考虑将disipyrroles A−D和Combretastatin A-4 (CA-4)作为杂化设计的可能成分。本研究以二吡咯C (Dis C)和CA-4为对照化合物,以合适的氨基酸前体为原料,通过其羰基中间体合成了4,5-二芳基- 1h -吡咯-3(2H)-化合物。其中,与CA-4具有完全取代模式的杂合物的效价和选择性优于Dis C,但活性低于CA-4。这种新的类似物通过与秋水仙碱位点结合抑制微管蛋白组装来破坏间期微管,诱导多极纺锤体,导致HeLa细胞周期阻滞和凋亡。它还能抑制乳腺癌细胞系的集落形成和迁移。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信